PTC Therapeutics held a community conference today regarding Ataluren. Stuart Peltz, President and CEO, PTC Therapeutics, Inc., welcomed and thanked the community as well as […]
Dear Duchenne Community, As you might have seen, the Office of Drug Evaluation I of the FDA provided a Complete Response Letter (CRL) for the application to market ataluren in […]
PTC Therapeutics received a Complete Response Letter from the Food and Drug Administration (FDA) for Ataluren’s New Drug Application (NDA). This means that the FDA has completed its review of […]
The 22nd International Annual Congress of the World Muscle Society took place in St Malo, between October 3 – 7, 2017. There were multiple breaking news stories on Duchenne muscular […]
Dear Duchenne Community, On behalf of all of PTC, we want to thank all of you for supporting the advisory committee review of ataluren. As you know, the meeting was […]
Today, Dr. Eric Olson spoke at the UT Southwestern Wellstone Muscular Dystrophy Center Duchenne Muscular Dystrophy Clinical Symposium. He presented promising pre-clinical data about gene editing using CRISPR/Cas9 for Duchenne. […]
CureDuchenne hosted a live Twitter chat on September 20 to raise awareness and address the important issues facing the Duchenne community. It was an opportunity to hear from patients, parents, […]
CureDuchenne is hosting a Twitter chat #DuchenneChat on September 20 at 11 a.m. PDT/2 p.m. EDT to raise awareness and address the important issues facing the Duchenne community. This Twitter […]
Dr. Kevin Flanigan from Nationwide Children’s Hospital provided an update on his Dup2 research during a CureDuchenne hosted call with families on September 6. Back in 2010, Dr. Flanigan told […]
